Studies are often done by pharmaceutical companies to determinethe effectiveness of a treatment program. Suppose that a new AIDSantibody drug is currently under study. It is given to patientsonce the AIDS symptoms have revealed themselves. Of interest is theaverage (mean) length of time in months patients live once startingthe treatment. Two researchers each follow a different set of 40AIDS patients from the start of treatment until their deaths. Thefollowing data (in months) are collected.

Researcher A: 3; 4; 11; 15; 16; 17; 22; 44; 37;16; 14; 24; 25; 15; 26; 27; 33; 29; 35; 44; 13; 21; 22; 10; 12; 8;40; 32; 26; 27; 31; 34; 29; 17; 8; 24; 18; 47; 33; 34

Researcher B: 3; 14; 11; 5; 16; 17; 28; 41; 31;18; 14; 14; 26; 25; 21; 22; 31; 2; 35; 44; 23; 21; 21; 16; 12; 18;41; 22; 16; 25; 33; 34; 29; 13; 18; 24; 23; 42; 33; 29

Complete the tables using the data provided. (Enter exactnumbers as integers, fractions, or decimals.)

Researcher A

Survival Length (in months)	Frequency	Relative Frequency	Cumulative Relative Frequency
0.5-6.5
6.5-12.5
12.5-18.5
18.5-24.5
24.5-30.5
30.5-36.5
36.5-42.5
42.5-48.5

Researcher B

Survival Length (in months)	Frequency	Relative Frequency	Cumulative Relative Frequency
0.5-6.5
6.5-12.5
12.5-18.5
18.5-24.5
24.5-30.5
30.5-36.5
36.5-45.5